ArticleThe oncologist2026
Predictive factors for early mortality after regorafenib or trifluridine/tipiracil initiation in metastatic colorectal cancer.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRegorafenib and trifluridine/tipiracil (FTD/TPI) are standard later-line treatments for patients with refractory metastatic colorectal cancer. However, these drugs show limited efficacy in some patients, and inappropriate use may increase toxicity and reduce quality of life. This study aimed to identify clinical predictors of early mortality after regorafenib or FTD/TPI initiation.
methodsWe retrospectively analyzed patients enrolled in the multicenter REGOTAS study. Early mortality was defined as death within 12 weeks of treatment initiation. Variables with P < .05 in univariate analysis were entered into a multivariable Cox model for overall survival (OS). Patients alive at 15 weeks (a 3-week margin beyond 12 weeks) were censored.
resultsWe analyzed 523 patients (regorafenib, N = 212; FTD/TPI, N = 311). Independent predictors of early mortality were Eastern Cooperative Oncology Group performance status (≥1), low albumin level (<3.5 g/dL), high C-reactive protein level (≥1.0 mg/dL), and short time from first-line chemotherapy initiation (<18 months). The high-risk group (patients with all four factors, N = 35) showed higher mortality and shorter OS than the low-risk group (others, N = 488): 12-week mortality rate 40% vs 14%, 14-week mortality rate 60% vs 18%, and median OS: 2.8 months vs 7.8 months (hazard ratio: 3.52; P-value < .0001).
conclusionOur predictive model may help identify patients at high risk of early mortality after regorafenib or trifluridine/tipiracil initiation and support shared decision-making between clinicians and patients regarding further chemotherapy or best supportive care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.